Drug intelligence / Profile preview

SLIM2401

Development stage: Preclinical
Lead developer: Samik Pharm
Modality: Small Molecules

Overview

SLIM2401 is a small molecule drug candidate being developed by Samik Pharmaceutical for the treatment of rheumatoid arthritis. It is classified as an "improved new drug" (incrementally modified drug) under South Korean regulatory frameworks, suggesting it is a new formulation, salt, or combination of an existing therapeutic agent designed to enhance clinical efficacy, safety, or patient compliance. As of 2024, the program is in the preclinical stage of development.

Other names: SLIM2401SLIM-2401SLIM 2401

Beyond the preview

Go deeper on SLIM2401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SLIM2401.

Explore the full profile